Ahead of sec­ond FDA chance, CorMedix winds down Eu­ro­pean busi­ness

The bear mar­ket struck again Thurs­day morn­ing as a New Jer­sey-based an­ti­fun­gal biotech re­port­ed a sig­nif­i­cant shift in op­er­a­tions.

CorMedix will be shak­ing up much …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER